Cinnarizine-Forte tablets 75mg №20

Cinnarizine-Forte tablets 75mg №20

Product Code: 6828
Availability: In Stock

Ask a question about this product


active substance:cinnarizine;

1 tablet contains zinnarizina, in terms of 100% substance 75 mg

other ingredients:lactose monohydrate, wax mountain glycol, ammonium-methacrylate copolymer (type A) ammonium-methacrylate copolymer dispersion; calcium stearate.


Dosage form


basic physical and chemical properties:white tablets with a creamy shade of color, chamfer, risk.


drug description

drugs used in vestibular disorders. ATC code N07C A02.


Pharmacological properties


Cinnarizine inhibits contractions of cells of vascular smooth muscle by blocking calcium channels. In addition to direct calcium antagonism, Cinnarizine reduces contractile effect of vasoactive substances such as norepinephrine and serotonin by blocking the calcium channels receptionservice. The blockade of calcium intake in cells is selective relative to tissues and leads to a reduction of vasoconstriction without affecting blood pressure and heart rate.

Zinnarizin can further improve insufficient microcirculation, increasing the ability of red blood cells to deformation and reducing blood viscosity. When it is taken, cellular resistance to hypoxia increases.

Cinnarizine inhibits stimulation of the vestibular system, which leads to suppression of nystagmus and other autonomic disorders. Using Cinnarizine is possible to prevent or relieve acute attacks of vertigo.


Maximum Cinnarizine levels in plasma achieved after 1-3 hours after ingestion. The half-life of zinnarizin from blood plasma is from 4 to 24 hours.

Zinnarizin is completely metabolized by the body. Excreted as metabolites: about 1/3 in the urine and 2/3 in the feces.

With blood plasma proteins binds about 91% of the drug.


Symptomatic treatment:

  • labyrinth disorders, including dizziness, tinnitus, nystagmus, nausea and vomiting;
  • cerebrovascular disorders, including dizziness, tinitis (tinitis), headache of vascular origin, irritability, memory impairment and ability to concentrate;
  • peripheral vascular disorders, including Raynaud's disease, acrocyanosis, intermittent lameness, trophic disorders, trophic and varicose ulcers, paresthesia, nocturnal convulsions in the limbs, feeling cold in the limbs.


Hypersensitivity to Cinnarizine and/or other components of the drug.


Interaction with other medicinal products and other forms of interaction

Alcohol/CNS depressants/tricyclic antidepressants:concomitant use may increase the sedative effect of any of these drugs or zinnarizin Forte.

Diagnostic procedures:thanks to the antihistamine action, Zinnarizin Forte can mask positive reactions to skin reactivity factors during the skin test, so its use should be stopped 4 days before it is carried out.

application Features

Zinnarizin Fortemay cause irritation in the epigastric region, taking the drug after meals will reduce irritation of the gastric mucosa.

patients with Parkinson's diseaseZinnarizin Forteis recommended only if the benefits of treatment exceed the possible risk of worsening the course of the disease.

SinceZinnarizin Fortecan cause drowsiness, especially at the beginning of treatment, one should refrain from the simultaneous use of alcohol and the use of means that inhibit the activity of the Central nervous system (CNS depressants).

Should be avoidedCinnarizine Forteporphyria.

Zinnarizin Forteshould be used with caution in patients with hepatic and/or renal failure.

the Drug contains lactose, so patients with rare hereditary forms of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome should not take this drug.

use during pregnancy or lactation.

Pregnancy.the use of the drug during pregnancy is possible if, according to the doctor, the expected positive effect for the mother exceeds the potential risk to the fetus.

breastfeeding Period.No data on the penetration Cinnarizine in breast milk, so women taking Cinnarizine Forte should abandon breastfeeding.

Ability to influence the reaction rate when driving motor transport or operating other mechanisms.

Given that sensitive patients may experience drowsiness when using the drug (especially at the beginning of treatment), at the time of taking the drug should refrain from driving and performing other works requiring concentration.

Method of application and doses

Adults Cinnarizine Forte is taken orally, preferably after meals.

for symptoms of cerebral circulation disorders: 1 tablet (75 mg) 1 time per day for symptoms of peripheral vascular disorders 2-3 tablets (150-225 mg) per day for symptoms of labyrinth disorders: 1 tablet (75 mg) 1 time per day.

the Maximum dose should not exceed 225 mg (3 tablets) per day. Since the effect of dizziness depends on the dose, the dose should be gradually increased.


This dosage form is not intended for the treatment of children.

Overdose rare cases of acute overdose (90 mg to 2250 mg), the following manifestations were observed: changes in consciousness from drowsiness to stupor and coma; vomiting, extrapyramidal symptoms, arterial hypotension. A small number of children had seizures. In most cases, the clinical result was not difficult, but it is known about lethal cases after overdose, while the use of other drugs, including zinnarizin.

Treatment.there is no Specific antidote. During the first hour after ingestion should be carried out gastric lavage. According to the testimony, you can assign the activated carbon.

Side effects

there May be symptoms such as drowsiness and disorders of the gastrointestinal tract. These simtoms are usually inevitable and can be avoided by gradually achieving an optimal dose.

headache, dry mouth, hypersensitivity (allergic reactions) and cholestatic jaundice may be observed.

the Cases of amplification or the development of extrapyramidal symptoms was observed mainly in the elderly in long-term care. In such cases, treatment should be discontinued.

The The The The The The The The The
adverse reactions
the immune system
Hypersensitivity (allergic reactions)
on the nervous system side
Drowsiness, headache, extrapyramidal disorders, hypersomnia, lethargy, dyskinesia, parkinsonism, tremor
from the digestive tract
Dry mouth, disorders of the gastrointestinal tract, feeling of discomfort in the stomach, nausea, vomiting, abdominal pain, dyspepsia.
on the part of the liver and biliary tract
cholestatic jaundice
on the part of the skin and subcutaneous fat
Rash, hyperhidrosis (excessive sweating), lichen planus, keratosis reseptive
on the part of the musculoskeletal system and connective tissue
Subacute cutaneous lupus erythematosus, muscle rigidity, fatigue
General violation
laboratory indicators
Increasing body mass

shelf Life

3 years.

storage Conditions

Store in its original packaging at a temperature not exceeding 25 ° C.

keep out of reach of children.



10 tablets per blister, 2 blisters in a pack.


Category vacation

According to the recipe.



OJSC "Kyivmedpreparat".

the manufacturer's Location and address of the place of business.

Ukraine, 01032, G.. Kiev, Saksaganskogo str., 139.


the product of pharmacological production is a drug and is used in the treatment of disorders in cerebral circulation and in the vestibular apparatus. Zinnarizin-the main active element, which is a selective blocker of calcium channels. Pharmacological effect is achieved by reducing the amount of calcium ions supplied, thereby reducing their tone smooth vascular muscles. 

the Tool also reduces the contractile activity constricts blood vessels,  substances (norepinephrine, serotonin); eliminates the dizzy spells, providing a depressing effect on the level of excitability of the vestibular apparatus. Effects on blood pressure and pulse has not. The drug has an enhanced effect due to an increased dose of the active substance (0.075 g). The package contains 20 tablets of white color.  


  1. ischemic stroke due to head injury or cerebral atherosclerosis.
  2. The
  3. Changes in blood flow in the brain after ischemic stroke.
  4. The
  5. Violation of peripheral blood flow. 
  6. The
  7. the Labyrinth changes.


the Preparation is taken orally, drinking plenty of water. Cinnarizine-KMP Forte is released only by prescription issued by your doctor. 

Write a review

Note: HTML is not translated!
    Bad           Good

Recently viewed © 2019